Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADZENYS ER vs ADDERALL 10
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ADZENYS ER is a central nervous system (CNS) stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft.
Adderall 10 contains a mixture of amphetamine salts (dextroamphetamine and levoamphetamine). Amphetamines are non-catecholamine sympathomimetic amines that promote the release of dopamine and norepinephrine from presynaptic neurons, inhibit their reuptake, and inhibit monoamine oxidase activity, thereby increasing extracellular levels of these neurotransmitters in the central nervous system.
Attention Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
Adults: Initial 5-10 mg orally once daily; titrate in 5-10 mg increments weekly to optimal response; max 60 mg/day.
10 mg orally once daily in the morning, with or without food; may increase by 5-10 mg weekly based on tolerability and response; usual effective dose 10-40 mg/day divided into 2-3 doses; maximum 60 mg/day.
6-8 hours in adults; in children 3-6 hours, requiring twice-daily dosing for sustained effect
Terminal elimination half-life: dextroamphetamine 9-11 hours, levoamphetamine 11-14 hours (Adderall is a mixed salt). In adults, mean half-life ~10 hours; in children, slightly shorter (6-8 hours). Clinical context: steady-state reached in 2-3 days; dosing interval typically 4-6 hours for immediate-release.
Metabolized primarily by hepatic esterases and cytochrome P450 (CYP) enzymes, including CYP2D6.
Amphetamine is metabolized primarily in the liver via cytochrome P450 enzymes, including CYP2D6, and undergoes deamination and oxidation to form inactive metabolites including 4-hydroxyamphetamine and norephedrine.
70% renal (30% unchanged, 40% as metabolites), 30% fecal/biliary
Renal: 70-80% (30-40% as unchanged amphetamine; remainder as deaminated and hydroxylated metabolites). Fecal: minimal (<5%). Biliary: negligible. Urinary p H affects excretion: acidic urine increases elimination, alkaline urine decreases.
97% bound to albumin and α1-acid glycoprotein
Amphetamine: 15-40% bound to plasma proteins (primarily albumin). Binding is not extensive, thus significant free fraction available for distribution.
4.6-6.8 L/kg, indicating extensive tissue distribution, particularly in brain and adipose tissue
Apparent Vd: 3.0-4.0 L/kg (for total amphetamine). High Vd indicates extensive tissue distribution, including brain. Clinical meaning: loading dose may be needed for rapid effect; distribution half-life ~1 hour.
Oral: 95% ± 10%; rectal: 80% ± 15%
Oral immediate-release: 100% (well-absorbed; first-pass metabolism minimal). Food delays absorption but does not affect extent. Extended-release: bioavailability similar to immediate-release with modified release profile.
GFR 30-89 m L/min: No adjustment. GFR <30 m L/min: Not recommended.
e GFR 15-29 m L/min: reduce dose by 50% and monitor for toxicity; e GFR <15 m L/min or dialysis: avoid use due to risk of accumulation; consider alternative therapy.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use due to decreased clearance and increased risk of toxicity.
Children ≥6 years: Initial 5-10 mg orally once daily; titrate weekly by 5-10 mg; max 1 mg/kg/day or 60 mg/day, whichever is lower.
Children 3-5 years: 2.5 mg orally once daily; may increase by 2.5 mg weekly; usual range 2.5-20 mg/day divided 1-2 times. Children 6 years and older: initial 5 mg once daily; may increase by 5 mg weekly; usual range 5-40 mg/day divided 1-3 times; maximum 40 mg/day.
Initiate at 5 mg once daily; titrate cautiously; monitor for cardiovascular effects and insomnia.
Initiate at 2.5-5 mg orally once daily; titrate slowly in increments of 2.5-5 mg weekly; monitor for cardiovascular effects, insomnia, and weight loss; maximum 40 mg/day.
WARNING: ABUSE AND DEPENDENCE. CNS stimulants, including ADZENYS ER, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.
Potential for abuse and dependence. Amphetamines have a high potential for abuse, which may lead to dependence and serious cardiovascular adverse events. Misuse may cause sudden death and serious cardiovascular events.
Serious cardiovascular events: Sudden death, stroke, and myocardial infarction have been reported in patients with pre-existing cardiac abnormalities.,Blood pressure and heart rate increase: Monitor regularly.,Psychiatric adverse reactions: May precipitate or exacerbate psychosis or mania.,Long-term suppression of growth in pediatric patients: Monitor height and weight.,Seizures: May lower seizure threshold in patients with history of seizures.,Peripheral vasculopathy: Including Raynaud's phenomenon.
Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities or other serious heart problems.,Blood pressure and heart rate increase; caution in hypertension and other cardiovascular conditions.,Psychiatric adverse events including exacerbation of psychosis, mania, and aggression.,Long-term suppression of growth in pediatric patients.,Peripheral vasculopathy including Raynaud's phenomenon.,Seizures: may lower seizure threshold.,Serotonin syndrome risk when co-administered with serotonergic drugs.
Known hypersensitivity to amphetamines or other components of ADZENYS ER,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI,Agitated states,History of drug abuse,Cardiovascular disease including hypertension, arteriosclerosis, hyperthyroidism, glaucoma
Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Known hypersensitivity or idiosyncrasy to sympathomimetic amines,Glaucoma,Agitated states,History of drug abuse,During or within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crises may occur)
High-fat meals can significantly delay and reduce the absorption of Adzenys ER; the time to peak concentration (Tmax) may be prolonged by approximately 1 hour and peak concentration (Cmax) reduced by about 38%. It is recommended to take Adzenys ER on an empty stomach (at least 1 hour before or 2 hours after a meal) to ensure consistent effect. Avoid alcohol while taking this medication, as it may increase the risk of cardiovascular side effects and impair judgment. No other specific food interactions are known, but patients should maintain a balanced diet to manage potential appetite suppression common with amphetamines.
High-fat meals can delay absorption; avoid acidic foods (e.g., citrus, cola) within 1 hour of dosing as they decrease absorption. Avoid caffeine; may increase stimulant effects.
First trimester: Inadequate human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second and third trimesters: Chronic use may lead to neonatal withdrawal syndrome (hyperactivity, irritability, poor feeding) and reduced fetal growth. Avoid in first trimester unless benefit outweighs risk; use lowest effective dose in later trimesters.
Pregnancy Category C. First trimester: potential increased risk of congenital malformations (e.g., gastroschisis, oral clefts) based on limited human data. Second and third trimesters: risk of fetal growth restriction, preterm delivery, and neonatal withdrawal symptoms (irritability, poor feeding).
Excreted in breast milk; M/P ratio approximately 2.6. Irritability and weight loss reported in nursing infants. Not recommended unless benefit outweighs risk.
Excreted into breast milk; relative infant dose estimated at 2-4% of maternal weight-adjusted dose. M/P ratio not well established. Manufacturer recommends caution; potential for infant agitation, insomnia, and growth suppression.
Clearance increased by approximately 30% in third trimester; may require dose escalation. Postpartum dose reduction may be needed to avoid toxicity. Individual titration based on clinical response and tolerability.
Increased plasma volume and enhanced hepatic metabolism may reduce amphetamine levels; dose adjustments should be individualized based on clinical response, but controlled studies lacking. Avoid abrupt discontinuation due to risk of withdrawal symptoms in mother and neonate.
Adzenys ER is an extended-release oral suspension of amphetamine (mixed salts) for ADHD. It provides a rapid onset (within 1 hour) and sustained effect over 10-12 hours. The suspension must be shaken vigorously for at least 10 seconds before each use. Dose titration should be guided by efficacy and tolerability, starting at 6.3 mg once daily in the morning for children 6-12 years. Avoid administration with high-fat meals as they may delay absorption (Cmax reduced by ~38%). Monitor for cardiovascular effects: heart rate, blood pressure, and potential for sudden death in patients with structural cardiac abnormalities. Use cautiously in patients with pyschosis, bipolar disorder, hypertension, hyperthyroidism, glaucoma, or history of drug abuse. Discontinue if agitation, aggression, or manic symptoms emerge. Drug holidays (weekend or holiday breaks) may be considered to assess need and reduce tolerance.
Adderall 10 mg contains immediate-release amphetamine salts. Onset of action is 30-60 minutes, duration 4-6 hours. Monitor for appetite suppression, insomnia, and cardiovascular effects. Avoid in patients with structural cardiac abnormalities or history of substance abuse. Use with caution in hypertension or hyperthyroidism. Drug holidays may reduce tolerance.
Take Adzenys ER exactly as prescribed, once daily in the morning; do not take in the afternoon or evening to avoid insomnia.,Shake the bottle vigorously for at least 10 seconds before each use; use the provided oral syringe to measure the correct dose.,Do not mix the medication with food or liquids; take it directly from the syringe.,Avoid taking with high-fat meals, as they may delay and reduce the drug's effect; take on an empty stomach if possible.,Store at room temperature (20-25°C); protect from light and moisture. Discard any unused portion after 30 days of opening.,Notify your doctor immediately if you experience chest pain, shortness of breath, fainting, or palpitations.,This medication has a high potential for abuse; do not share it with others and keep in a safe place.,Inform your doctor about all other medications, including OTC drugs and supplements, especially MAOIs (avoid within 14 days), antihypertensives, and SSRIs.
Take exactly as prescribed; do not crush or chew tablets.,Take early in the day to prevent insomnia.,May cause weight loss; monitor growth in children.,Avoid alcohol and decongestants (risk of hypertensive crisis).,Report chest pain, palpitations, or shortness of breath immediately.,Do not drive if you feel dizzy or impaired.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADZENYS ER vs ADDERALL 10, answered by our medical review team.
ADZENYS ER is a CNS Stimulant that works by ADZENYS ER is a central nervous system (CNS) stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft.. ADDERALL 10 is a CNS Stimulant that works by Adderall 10 contains a mixture of amphetamine salts (dextroamphetamine and levoamphetamine). Amphetamines are non-catecholamine sympathomimetic amines that promote the release of dopamine and norepinephrine from presynaptic neurons, inhibit their reuptake, and inhibit monoamine oxidase activity, thereby increasing extracellular levels of these neurotransmitters in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADZENYS ER and ADDERALL 10 depend on the specific clinical indication. These are both CNS Stimulant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADZENYS ER is: Adults: Initial 5-10 mg orally once daily; titrate in 5-10 mg increments weekly to optimal response; max 60 mg/day.. The standard adult dose of ADDERALL 10 is: 10 mg orally once daily in the morning, with or without food; may increase by 5-10 mg weekly based on tolerability and response; usual effective dose 10-40 mg/day divided into 2-3 doses; maximum 60 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADZENYS ER and ADDERALL 10 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADZENYS ER is classified as Category C. First trimester: Inadequate human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second and third trimesters: Chronic use may lead to neonata. ADDERALL 10 is classified as Category C. Pregnancy Category C. First trimester: potential increased risk of congenital malformations (e.g., gastroschisis, oral clefts) based on limited human data. Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.